72 related articles for article (PubMed ID: 28805110)
1. Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system.
Liptrott NJ; Giardiello M; McDonald TO; Rannard SP; Owen A
Nanomedicine (Lond); 2017 Sep; 12(17):2043-2054. PubMed ID: 28805110
[TBL] [Abstract][Full Text] [Related]
2. Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.
Liptrott NJ; Giardiello M; McDonald TO; Rannard SP; Owen A
J Nanobiotechnology; 2018 Mar; 16(1):22. PubMed ID: 29544545
[TBL] [Abstract][Full Text] [Related]
3. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment.
Patel G; Shelat P; Lalwani A
Drug Deliv; 2016 Oct; 23(8):3027-3042. PubMed ID: 26882014
[TBL] [Abstract][Full Text] [Related]
4. Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.
Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
Biochem Biophys Res Commun; 2013 Jul; 437(2):199-204. PubMed ID: 23792096
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-κB and PPAR-γ.
Alves ÉAR; de Miranda MG; Borges TK; Magalhães KG; Muniz-Junqueira MI
Int Immunopharmacol; 2015 Feb; 24(2):314-324. PubMed ID: 25545854
[TBL] [Abstract][Full Text] [Related]
6. Suppression of HIV-1 Viral Replication by Inhibiting Drug Efflux Transporters in Activated Macrophages.
Mu Y; Cory TJ
Curr HIV Res; 2021; 19(2):128-137. PubMed ID: 33032513
[TBL] [Abstract][Full Text] [Related]
7. QbD based development of proliposome of lopinavir for improved oral bioavailability.
Patel GM; Shelat PK; Lalwani AN
Eur J Pharm Sci; 2017 Oct; 108():50-61. PubMed ID: 27586019
[TBL] [Abstract][Full Text] [Related]
8. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
Pham K; Li D; Guo S; Penzak S; Dong X
J Control Release; 2016 Mar; 226():88-97. PubMed ID: 26849919
[TBL] [Abstract][Full Text] [Related]
9. Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.
Fagone P; Mangano K; Quattrocchi C; Cavalli E; Mammana S; Lombardo GA; Pennisi V; Zocca MB; He M; Al-Abed Y; Nicoletti F
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):306-15. PubMed ID: 25903922
[TBL] [Abstract][Full Text] [Related]
10. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.
Ravi PR; Vats R; Dalal V; Murthy AN
J Pharm Pharmacol; 2014 Jul; 66(7):912-26. PubMed ID: 24697749
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A
HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model.
Ravi PR; Vats R
J Pharm Pharmacol; 2017 Jul; 69(7):823-833. PubMed ID: 28317117
[TBL] [Abstract][Full Text] [Related]
13. Design, optimization and evaluation of poly-ε-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir.
Ravi PR; Vats R; Dalal V; Gadekar N; N A
Drug Dev Ind Pharm; 2015 Jan; 41(1):131-40. PubMed ID: 24180260
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
[TBL] [Abstract][Full Text] [Related]
16. Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.
Mandal A; Pal D; Mitra AK
Int J Pharm; 2016 Oct; 512(1):49-60. PubMed ID: 27543355
[TBL] [Abstract][Full Text] [Related]
17. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Masse S; Lu X; Dekhtyar T; Lu L; Koev G; Gao F; Mo H; Kempf D; Bernstein B; Hanna GJ; Molla A
Antimicrob Agents Chemother; 2007 Sep; 51(9):3075-80. PubMed ID: 17576848
[TBL] [Abstract][Full Text] [Related]
18. HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance.
Vivithanaporn P; Asahchop EL; Acharjee S; Baker GB; Power C
AIDS; 2016 Feb; 30(4):543-52. PubMed ID: 26558720
[TBL] [Abstract][Full Text] [Related]
19. Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells.
Basile MS; Mazzon E; Krajnovic T; Draca D; Cavalli E; Al-Abed Y; Bramanti P; Nicoletti F; Mijatovic S; Maksimovic-Ivanic D
Molecules; 2018 Sep; 23(10):. PubMed ID: 30261624
[TBL] [Abstract][Full Text] [Related]
20. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
